Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing number of cross industry collaboration and partnership
3.2.1.2 Artificial intelligence reduces cost and time utilized in the drug discovery & development process
3.2.1.3 Rising prevalence of chronic and infectious diseases
3.2.2 Industry pitfalls & challenges
3.2.2.1 Lack of data sets in the field of drug discovery
3.2.2.2 Limited understanding and expertise
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 AI in drug discovery - drugs by stage and therapeutic area
3.6 Funding received for AI in drug discovery, 2018-2020
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Investment and partnership landscape
4.2.1 Investment landscape
4.2.2 Partnership landscape
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Component, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Software
5.3 Services
Chapter 6 Market Estimates and Forecast, By Technology, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Machine learning
6.2.1 Deep learning
6.2.2 Supervised learning
6.2.3 Unsupervised learning
6.2.4 Other machine learning technologies
6.3 Other technologies
Chapter 7 Market Estimates and Forecast, By Application Type, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Molecular library screening
7.3 Target identification
7.4 Drug optimization and repurposing
7.5 De novo drug designing
7.6 Preclinical testing
Chapter 8 Market Estimates and Forecast, By Therapeutic Area, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Oncology
8.3 Neurodegenerative diseases
8.4 Inflammatory diseases
8.5 Infectious diseases
8.6 Metabolic diseases
8.7 Rare diseases
8.8 Cardiovascular diseases
8.9 Other therapeutic areas
Chapter 9 Market Estimates and Forecast, By End-Use, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 Pharmaceutical and biotechnology companies
9.3 Contract research organization (CROs)
9.4 Other end-users
Chapter 10 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 Alphabet Inc. (DeepMind)
11.2 Atomwise Inc.
11.3 BenevolentAI
11.4 Cyclica
11.5 Deep Genomic
11.6 Deargen Inc.
11.7 Exscientia
11.8 International Business Machines Corporation
11.9 Microsoft Corporation
11.10 NVIDIA Corporation
